By Fineline Cube 
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315; SHA: 688796) announced that it has signed a non‑exclusive licensing agreement with Qilu Pharmaceutical for a fully human nanobody molecule, supporting Qilu’s R&D exploration in innovative neurological drug projects. The collaboration, built on Biocytogen’s proprietary RenNano platform, delivers an upfront payment with milestone eligibility and extends the company’s discovery engine into one of pharma’s most challenging therapeutic frontiers — the central nervous system.
Deal Terms at a Glance
| Item | Detail |
|---|---|
| Parties | Biocytogen (HKG: 2315; SHA: 688796) and Qilu Pharmaceutical |
| Structure | Non‑exclusive licensing agreement |
| Asset | Fully human nanobody molecule (RenNano platform‑derived) |
| Purpose | Support Qilu Pharmaceutical’s R&D in innovative neurological drug projects |
| Upfront Payment | Undisclosed amount, confirmed as part of the agreement |
| Milestones | Eligible development, regulatory, and commercial milestone payments |
| Other Financial Terms | Not disclosed |
Platform & Asset Profile
- Platform: RenNano — Biocytogen’s proprietary fully human nanobody discovery platform
- Asset Characteristics: Fully human nanobody molecule, licensable for further R&D aligned with the partner’s own strategy
- Development Flexibility: Subsequent development forms of the project will be flexibly advanced based on project characteristics and therapeutic needs
- Deal Nature: Non‑exclusive structure allows Biocytogen to retain broader platform optionality across multiple partners and programs
Market Impact & Outlook
- Neurology frontier: Qilu Pharmaceutical’s application of the nanobody molecule to innovative neurological drug projects targets an area of high unmet need, where novel modalities are actively sought
- Platform validation: The RenNano‑derived asset licensing reinforces Biocytogen’s positioning as a discovery‑platform partner for major domestic pharmaceutical companies
- Scalable economics: The upfront plus milestone structure provides near‑term revenue with upside tied to downstream development success, while the non‑exclusive format preserves Biocytogen’s ability to monetize the platform repeatedly
- Strategic fit: For Qilu Pharmaceutical, one of China’s leading generic‑to‑innovative drug companies, the deal adds differentiated biologics capability to its neurological pipeline exploration
Forward‑Looking Statements — This brief contains forward‑looking statements regarding the development plans, milestone achievement, and commercial potential of the licensed nanobody molecule in neurological indications. Additional financial terms were not disclosed. Actual results may differ materially due to scientific, regulatory, competitive, and market risks. No investment decision should be made solely on the basis of this brief.-Fineline Info & Tech